Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

[1]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[2]  P. Black,et al.  2239 CLINICAL AND GENOMIC ANALYSIS OF METASTATIC DISEASE PROGRESSION IN A BACKGROUND OF BIOCHEMICAL RECURRENCE , 2013 .

[3]  Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group , 2013, Oncotarget.

[4]  P. Dahm,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.

[5]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[6]  M. Zelefsky,et al.  High-risk prostate cancer: from definition to contemporary management. , 2012, European urology.

[7]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[8]  O. Brawley.  Prostate cancer epidemiology in the United States , 2012, World Journal of Urology.

[9]  M. Graefen,et al.  The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis , 2012, Advances in urology.

[10]  T. Triche,et al.  Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers , 2011, Front. Gene..

[11]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[12]  M. Cooperberg,et al.  The CAPRA‐S score , 2011, Cancer.

[13]  V. Laudone,et al.  Reverse stage shift at a tertiary care center , 2011, Cancer.

[14]  John T. Wei,et al.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression , 2011, Nature Biotechnology.

[15]  R. Thompson,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[16]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[17]  J. Einasto.  Dark Matter , 2011, Brazilian Journal of Physics.

[18]  Ronald C. Chen,et al.  Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. , 2011, The Journal of urology.

[19]  G. Swanson,et al.  Prognostic Factors for Failure after Prostatectomy , 2010, Journal of Cancer.

[20]  Mihaela Aslan,et al.  Impact of biochemical recurrence in prostate cancer among US veterans. , 2010, Archives of internal medicine.

[21]  K. D. Sørensen,et al.  Discovery of prostate cancer biomarkers by microarray gene expression profiling , 2010, Expert review of molecular diagnostics.

[22]  C. Lawton.  Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .

[23]  Andrew J Vickers,et al.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.

[26]  R. Thompson,et al.  Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? , 2007, The Journal of urology.

[27]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[28]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  William J Catalona,et al.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.

[30]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  Z. Ying,et al.  Cox Regression with Incomplete Covariate Measurements , 1993 .